

EUROPEAN PATENT APPLICATION

Application number: 83302824.4

Int. Cl.³: **C 07 D 311/68**
C 07 D 311/70

Date of filing: 18.05.83

Priority: 21.05.82 GB 8214821
15.01.83 GB 8301088

Date of publication of application:
30.11.83 Bulletin 83/48

Designated Contracting States:
BE CH DE FR GB IT LI NL SE


Applicant: **BEECHAM GROUP PLC**
Beecham House Great West Road
Brentford Middlesex(GB)

Inventor: **Evans, John Morris**
'Cata' Old House Lane
Roydon Essex(GB)

Representative: **Stott, Michael John et al,**
European Patent Attorney Beecham Pharmaceuticals
Great Burgh Yew Tree Bottom Road
Epsom Surrey KT18 5XQ(GB)

Pharmaceutically active aminobenzopyrans.

Compounds of formula (I):



wherein:

either one of R₁ and R₂ is hydrogen and the other is selected from the class of C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxy-carbonyl, C₁₋₆ alkylcarbonyloxy, C₁₋₆ alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C₁₋₆ alkylsulphinyl, C₁₋₆ alkylsulphonyl, C₁₋₆ alkoxy-sulphinyl, C₁₋₆ alkoxy-sulphonyl, C₁₋₆ alkylcarbonylamino, C₁₋₆ alkoxy-carbonylamino, C₁₋₆ alkyl-thiocarbonyl, C₁₋₆ alkoxy-thiocarbonyl, C₁₋₆ alkyl-thiocarbonyloxy, C₁₋₆ alkyl-thiolmethyl, formyl or aminosulphiny, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C₁₋₆ alkyl groups, or C₁₋₆ alkylsulphinylamino, C₁₋₆ alkylsulphonylamino, C₁₋₆ alkoxy-sulphinylamino or C₁₋₆ alkoxy-sulphonylamino or ethylenyl terminally substituted by C₁₋₆ alkylcarbonyl, nitro or cyano, or -C(C₁₋₆ alkyl)NOH or -C(C₁₋₆ alkyl)NNH₂, or one of R₁ and R₂ is nitro, cyano or C₁₋₃ alkylcarbonyl and the other

is methoxy or amino optionally substituted by one or two C₁₋₆ alkyl or by C₂₋₇ alkanoyl;

one of R₃ and R₄ is hydrogen or C₁₋₄ alkyl and the other is C₁₋₄ alkyl or R₃ and R₄ together with the carbon atom to which they are attached are C₂₋₅ polymethylene;

either R₅ is hydroxy, C₁₋₆ alkoxy or C₂₋₇ acyloxy and R₆ is hydrogen or R₅ and R₆ together are a bond;

R₇ is hydrogen, C₁₋₆ alkyl optionally substituted by hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl or carboxy, or C₁₋₂ alkyl substituted by halogen, or C₂₋₆ alkenyl;

R₈ is hydrogen or C₁₋₆ alkyl; and

X is oxygen or sulphur; the R₈-N-CX-R₇ group being trans to the R₅ group when R₅ and R₆ together are not a bond; or, when one or the other of R₁ and R₂ is an amino or an amino-containing group, a pharmaceutically acceptable salt thereof, having anti-hypertensive activity.

0095316


B1264/1380

TITLE MODIFIED
see front page

ACTIVE COMPOUNDS

The present invention relates to novel benzopyrans having pharmacological activity, to a process and intermediates for preparing them, to pharmaceutical compositions containing them, and to their use in the treatment of mammals.


U.S. Patent 4 110 347 discloses compounds having blood pressure lowering activity which are of formula (A'):



(A')

and acid addition salts thereof wherein, R_a is a hydrogen atom or a C_{1-9} hydrocarbon group optionally substituted by a hydroxyl or C_{1-6} alkoxy group; R_b is a hydrogen atom or C_{1-6} alkyl group, or NR_aR_b is a 3-8 membered heterocyclic group optionally substituted by one or two methyl groups; R_c is a hydrogen or halogen atom or a C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} alkoxy, C_{2-6} alkenoxyl, C_{1-6} alkylthio, hydroxyl, amino, C_{1-6} alkylamino, C_{1-6} dialkylamino, nitro, trifluoromethyl, C_{2-7} acylamino, C_{1-6} alkoxysulphonylamino, carboxyl, nitrile or AOR_g , ASR_g , ASO_2R_g , $ANHR_g$, ANR_gCOR_h , $ANR_gSO_2R_h$ or $ANR_gCO_2R_h$ group, in which A is an alkylene group of 1-4 carbon, R_g is an alkyl group of 1-4 carbon atoms, and R_h is an alkyl group of 1 to 4 carbon atoms; and R_d is a hydrogen or halogen atom or methyl or methoxy, or R_c together with R_d forms a $-CH=CH-CH=CH-$, $-NH-CH=CH-$, $-CH_2-CH_2-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-CO-$ system; R_e is a hydrogen atom or a C_{1-6} alkyl or phenyl group; and R_f is a hydrogen atom or a C_{1-6} alkyl or phenyl group.


U.S. Patent 4 251 532 discloses compounds having useful anti-hypertensive activity, which are of formula (B'):



wherein R_i is a hydrogen atom or an alkyl group of up to 4 carbon atoms optionally substituted by a chlorine or bromine atom or by a hydroxyl group or by an alkoxy group of up to 4 carbon atoms or by an acyloxy group of

up to 4 carbon atoms and R_j is a hydrogen atom or an alkyl group of up to 4 carbon atoms or R_i is joined to R_j so that together with the nitrogen atom to which they are attached they form a 5-, 6- or 7-membered heterocyclic ring which is optionally substituted by methyl; Y is a group COR_k , CO_2R_k , SOR_k , SO_2R_k , $SOOR_k$, SO_2OR_k , $CH(OH)R_k$, $C(R_k)=NOH$, $C(R_k)=NNH_2$, $CONH_2$, $CONR_1R_m$, $SONR_1R_m$ or $SO_2NR_1R_m$ where R_k and R_l are each independently a hydrocarbon group of up to 8 carbon atoms or such a group inertly substituted by a chlorine or bromine atom or by a hydroxyl group or by an alkoxy group of 1-4 carbon atoms or by an acyloxy group of up to 4 carbon atoms or by 3 fluorine atoms attached to the same carbon atom and R_m is a hydrogen atom or an alkyl group of up to 4 carbon atoms; and salts thereof and O-acyl derivatives thereof wherein the O-acyl moiety contains up to 18 carbon atoms.

European Patent Publications 28064 and 28449 describe compounds having blood pressure lowering activity, with low levels of unwanted cardiac effects, which compounds are of formula (C'):




wherein:

- R_n is a hydrogen atom or a lower alkyl group;
- R_o is a hydrogen atom or a lower alkyl group;
- R_p is a hydrogen atom or a lower alkyl group;
- R_q is a hydrogen atom or a lower alkyl group;
- R_r is a lower alkyl or a substituted alkyl group;
- or R_q and R_r are joined so that together with the

nitrogen atom to which they are attached they form a 5-, 6- or 7-membered ring optionally containing an oxygen or sulphur atom;

one of R_S and R_t is an electron withdrawing group and the other is an electron donating group; and the NR_qR_r and OR_p moieties are trans.

U.S. Patent 4 119 643 discloses compounds having anti-hypertensive activity, which are of formula (D'):



wherein:

R_n and R_o are as defined for formula (C');;

R_v is a hydrogen atom or $-COR_z$, wherein R_z is a C_{1-8} hydrocarbon group optionally substituted by halogen or hydroxy;

R_w is a hydrogen atom or a C_{1-4} alkyl group;

R_x is a group $-X-Y$, wherein X is an alkylene group of 2 to 6 carbon atoms and Y is a halogen atom, or a OZ group, wherein Z is a C_{1-7} hydrocarbon, methanesulphonyl, toluene-p-sulphonyl or phenylsulphonyl; and


R_y is a hydrogen, fluorine or chlorine atom or a hydroxy, methoxy or methyl group.

A further class of benzopyrans have now been discovered which are characterised by the presence of a an acyclic carbonylamino- or thiocarbonylamino-

0095316

containing group which substitutes the benzopyran in the 4-position. Moreover, such benzopyrans have been found to have blood pressure lowering activity.

Accordingly, the present invention provides a compound of formula (I):



(I)

wherein:

either one of R₁ and R₂ is hydrogen and the other is selected from the class of C₁-6 alkylcarbonyl, C₁-6 alkoxy carbonyl, C₁-6 alkylcarbonyloxy, C₁-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C₁-6 alkylsulphinyl, C₁-6 alkylsulphonyl, C₁-6 alkoxy sulphinyl, C₁-6 alkoxy sulphonyl, C₁-6 alkylcarbonylamino, C₁-6 alkoxy carbonylamino, C₁-6 alkylthiocarbonyl, C₁-6 alkoxythiocarbonyl, C₁-6 alkylthiocarbonyloxy, C₁-6 alkylthiolmethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C₁-6 alkyl groups, or C₁-6 alkylsulphinylamino, C₁-6 alkylsulphonylamino, C₁-6 alkoxy sulphinylamino or C₁-6 alkoxy sulphonylamino or ethylenyl terminally substituted by C₁-6 alkylcarbonyl, nitro or cyano, or -C(C₁-6 alkyl)NOH or -C(C₁-6 alkyl)NNH₂, or one of R₁

02 and R₂ is nitro, cyano or C₁₋₃ alkylcarbonyl and the
03 other is methoxy or amino optionally substituted by one
04 or two C₁₋₆ alkyl or by C₂₋₇ alkanoyl;

05
06 one of R₃ and R₄ is hydrogen or C₁₋₄ alkyl and the
07 other is C₁₋₄ alkyl or R₃ and R₄ together with the
08 carbon atom to which they are attached are
09 C₂₋₅ polymethylene;

10
11 either R₅ is hydroxy, C₁₋₆ alkoxy or C₂₋₇ acyloxy
12 and R₆ is hydrogen or R₅ and R₆ together are a bond;

13 hydrogen, or
14 R₇ is C₁₋₆ alkyl optionally substituted by
15 hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl or carboxy,
16 or C₁₋₂ alkyl substituted by halogen, or C₂₋₆ alkenyl;

17
18 R₈ is hydrogen or C₁₋₆ alkyl; and

19
20 X is oxygen or sulphur; the R₈-N-CX-R₇ group being
21 trans to the R₅ group when R₅ and R₆ together are not a
22 bond; or, when one or the other of R₁ and R₂ is an
23 amino or an amino-containing group, a pharmaceutically
24 acceptable salt thereof.

25
26 When one of R₁ and R₂ is hydrogen, the other is
27 preferably selected from the class of
28 C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxycarbonyl,
29 C₁₋₆ alkylcarbonyloxy, C₁₋₆ alkylhydroxymethyl, nitro
30 or cyano. In particular, when one of R₁ and R₂ is
31 hydrogen, the other is preferably nitro or cyano.

32
33 When one of R₁ and R₂ is hydrogen, it is preferred
34 that R₂ is hydrogen.

35
36 When one of R₁ and R₂ is nitro, cyano or
37 C₁₋₃ alkylcarbonyl the other is preferably amino
38 optionally substituted by one or two C₁₋₆ alkyl or by
39 C₂₋₇ alkanoyl. In particular, when one of R₁ and R₂ is

nitro, cyano or C₁₋₃ alkylcarbonyl, the other is amino, methylamino, dimethylamino or acetylamino. Most preferably, one of R₁ and R₂ is nitro or cyano, especially cyano, and the other is amino.

When one of R₁ and R₂ is nitro, cyano or C₁₋₃ alkylcarbonyl, it is preferred that R₁ is nitro, cyano or C₁₋₃ alkylcarbonyl.

The alkyl groups or alkyl moieties of alkyl-containing groups for R₁ or R₂ are, preferably, methyl or ethyl.

Preferably, R₃ and R₄ are both C₁₋₄ alkyl. In particular, they are both methyl or ethyl, preferably both methyl.

When R₅ is C₁₋₆ alkoxy and R₆ is hydrogen, preferred examples of R₅ include methoxy and ethoxy, of which methoxy is more preferred. When R₅ is C₂₋₇ acyloxy and R₆ is hydrogen, a preferred class of R₅ is unsubstituted carboxylic acyloxy, such as unsubstituted aliphatic acyloxy or benzoyloxy. However, it is preferred that R₅ and R₆ together are a bond, or, in particular, R₅ is hydroxy and R₆ is hydrogen.

Examples of R₇, when C₁₋₆ alkyl, include methyl, ethyl and n- and iso-propyl. Preferably R₇, when C₁₋₆ alkyl, is methyl.

Examples of R₇, when C₁₋₆ alkyl substituted by hydroxy, include methyl or ethyl terminally substituted by hydroxy.

A sub-class of R₇, when C₁₋₆ alkyl substituted by C₁₋₆ alkoxy, is C₁₋₆ alkyl substituted by methoxy or ethoxy. Examples thereof include methyl or ethyl

0095316

terminally substituted by methoxy or ethoxy.

A sub-class of R₇, when C₁₋₆ alkyl substituted by C₁₋₆ alkoxy carbonyl, is C₁₋₆ alkyl substituted by methoxy carbonyl or ethoxy carbonyl. Examples thereof include methyl or ethyl terminally substituted by methoxy carbonyl or ethoxy carboxy.

Examples of R₇, when C₁₋₆ alkyl substituted by carboxy, include methyl or ethyl terminally substituted by carboxy.

A sub-class of R₇, when C₁₋₂ alkyl substituted by halogen, is methyl or ethyl terminally substituted by chloro or bromo, in particular by chloro.

Examples of R₇, when C₂₋₆ alkenoyl, include vinyl, prop-1-enyl, prop-2-enyl, 1-methylinyl, but-1-enyl, but-2-enyl, but-3-enyl, 1-methylenepropyl, or 1-methylprop-2-enyl, in both their E and Z forms where stereoisomerism exists.

Examples of R₈ include hydrogen, methyl, ethyl, n- or iso-propyl. Preferably, R₈ is hydrogen or methyl, especially hydrogen.

Examples of a pharmaceutically acceptable salt of a compound of formula (I), when one or the other of R₁ and R₂ is an amino or an amino-containing group, include the hydrochloride and hydrobromide salts.

Preferably, a compound of formula (I) is in substantially pure form.

The compounds of formula (I), wherein R₅ is hydroxy, C₁₋₆ alkoxy or C₂₋₇ acyloxy and R₆ is hydrogen, are dissymmetric and, therefore, can exist as

stereoisomers. The present invention extends to all such stereoisomers individually and as mixtures, such as racemic modifications.

Examples of compounds of formula (I) include the compounds prepared in the Examples hereinafter. Of these, those that are particularly preferred include:


trans-4-N-acetylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol;

trans-4-N-acetylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-yl acetate;

trans-4-N-acetylamino-6-acetyl-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol; and

trans-4,7-bis(acetylamino)-6-nitro-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol.

The present invention also provides a process for preparing a compound of formula (I), which comprises acylating a compound of formula (II):



wherein R₁' and R₂' are R₁ and R₂, as defined hereinbefore, or a group or atom convertible thereto, R₃, R₄ and R₈ are as defined hereinbefore, R₅' is hydroxy, C₁₋₆ alkoxy or C₂₋₇ acyloxy and R₆' is hydrogen, the R₈NH group being trans to the R₅' group, with an acylating agent of formula (III):

02

03

R₇-CO-L₁

(III)

04

05

06

07

08

09

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

wherein R₇ is as defined hereinbefore and L₁ is a leaving group; in the case where R₁ or R₂ is a group or atom convertible into R₁ or R₂, converting the group or atom into R₁ or R₂; optionally converting R₁, R₂ or R₅ in the resulting compound of formula (I) into another R₁, R₂ or R₅; in the case where R₅ and R₆ in the resulting compound of formula (I) are hydroxy and hydrogen respectively, optionally dehydrating the compound to give another compound of formula (I), wherein R₅ and R₆ together are a bond; optionally thiating the R₈-N-CO-R₇ group in the resulting compound of formula (I) to give another compound of formula (I), wherein X is sulphur; and, when one or the other of R₁ and R₂ in the resulting compound of formula (I) is amino or an amino-containing group, optionally forming a pharmaceutically acceptable salt.

The leaving group (L₁) is a group that is displaceable by a primary or secondary amino nucleophile. Examples of such a group include C₂-9 acyloxy, such as mesyloxy, tosyloxy, triflate and C₁-4 alkylcarbonyloxy, and halogen, such as chloro and bromo. When the leaving group (L₁) is either of these examples, the acylating agent of formula (III) is either an acid anhydride or an acid halide. When it is acid anhydride, it may be a mixed or simple anhydride. If it is a mixed anhydride, it may be prepared in situ from a carboxylic acid and an acid halide.

When the acylating agent of formula (III) is an acid anhydride, the acylation of the compound of formula (II) is, preferably, carried out using the anhydride as the solvent in the presence of an acid acceptor, such as sodium acetate.

0095316

2 When the acylating agent of formula (III) is an
3 acid halide, the acylation of the compound of formula
4 (II) is, preferably, carried out in an aqueous medium,
5 such as chloroform/water, in the presence of an acid
6 acceptor, such as triethylamine, trimethylamine,
7 pyridine, picoline or calcium, potassium or sodium
8 carbonate.

9 When R_5' in a compound of formula (II) is hydroxy,
1 there is a risk of a side-reaction between the hydroxy
2 group and the acylating agent of formula (III). It is,
3 therefore, preferred that either R_5' is C_{2-7} acyloxy in
4 a compound of formula (II) and, after reaction with the
5 acylating agent of formula (III), is converted into
6 hydroxy, as described hereinafter. It is however, even
7 more preferred that the reaction is controlled such
8 that only the amine, R_8NH- , is acylated, for example,
9 by using a C_{2-9} acyloxy group as the leaving group
0 (L_1), in the acylating agent of formula (III) in the
1 manner as previously described for an acid anhydride.

2 Conversions of an aromatic group into R_1 or R_2 , as
3 defined hereinbefore, are generally known in the art of
4 aromatic chemistry. For example, it is preferred when
5 carrying out the acylation of a compound of formula
6 (II), first to protect any unsubstituted terminal
7 amine, that may be present for R_1 or R_2 , such as amino
8 aminosulphinyl, aminosulphonyl or aminocarbonyl, and
9 afterwards to convert the protected amino moiety into
0 the required terminal amine. Examples of protecting
1 agents include acyl groups, such as acetyl, which may
2 be added and removed conventionally. If it is desired
3 to protect a terminal amino moiety in the presence of a
4 cyano group then a more appropriate method is to use a
5 trifluoroacetyl protecting group which may be removed
6 by mild hydrolysis or to use a benzyloxycarbonyl or a
7

02 p-nitrobenzyloxycarbonyl protecting group which may be
03 removed by mild catalytic hydrogenolysis.
04

05 If the optional thiation reaction is to be carried
06 out in order to obtain a compound of formula (I),
07 wherein one or the other of R₁ and R₂ is a
08 carbonyl-containing group and X is sulphur, it is
09 preferred to use in the acylation reaction the
10 corresponding compound of formula (II), wherein R₁' or
11 R₂' is a protected carbonyl-containing group, and
12 after thiation to convert the protected
13 carbonyl-containing group into the required
14 carbonyl-containing group for R₁ or R₂. Without such
15 protection, the additional carbonyl group may give rise
16 to a competing side-reaction. Examples of preferred
17 carbonyl protecting groups include ketalising agents,
18 which may be added and removed in conventional manner.
19

20 Examples of an optional conversion of R₁ or R₂ in
21 the resulting compound of formula (I) into another R₁
22 or R₂, as defined hereinbefore, include the optional
23 conversion of an α-hydroxyethyl group into acetyl by
24 oxidation, the optional conversion of a chloro atom
25 into an amino group by amination, the optional
26 conversion of an amino group into an amino group
27 substituted by one or two C₁₋₆ alkyl or by C₂₋₇
28 alkanoyl, or the optional conversion of a hydrogen atom
29 into a nitro group by nitration.
30

31 Examples of an optional conversion of R₅ in a
32 compound of formula (I) into another R₅ are generally
33 known in the art. For example, when R₅ is hydroxy, it
34 may be alkylated using an alkyl iodide in an inert
35 solvent, such as toluene, in the presence of a base,
36 such as potassium hydroxide, or it may be acylated
37 using a carboxylic acid chloride or anhydride in a
38 non-hydroxylic solvent in the presence of a

condensation promoting agent, such as dicyclohexylcarbodiimide. Alternatively, when R₅ is C₂₋₇ acyloxy or it may be converted into hydroxy by conventional hydrolysis with for example, dilute mineral acid.

The optional dehydration of a resulting compound of formula (I), wherein R₅ and R₆ are hydroxy and hydrogen respectively, into another compound of formula (I), wherein R₅ and R₆ together are a bond, may be carried out in accordance with conventional dehydration conditions, for example, by using a dehydrating agent, such as sodium hydride, in an inert solvent, such as dry tetrahydrofuran, at reflux temperature.


The optional thiation of the R₈-N-CO-R₇ group in a compound of formula (I) to give another compound of formula I, wherein X is sulphur, is, preferably, carried out with conventional thiation agents, such as hydrogen sulphide, phosphorous pentasulphide and Lawesson's reagent (p-methoxyphenylthiophosphine sulphide dimer). The use of hydrogen sulphide and phosphorous pentasulphide may lead to side-reactions and, therefore, the use of Lawesson's reagent is preferred.

The thiation reaction conditions are conventional for the thiation agent employed. For example, the use of hydrogen sulphide is, preferably, acid catalysed by, for example, hydrogen chloride in a polar solvent, such as acetic acid or ethanol. The preferred use of Lawesson's reagent is preferably carried out under reflux in a dry solvent, such as toluene or methylene chloride.

The optional formation of a pharmaceutically acceptable salt, when one or the other of R₁ and R₂ in the resulting compound of formula (I) is amino or an

02 amino-containing group, may be carried out
03 conventionally.
04

05 A compound of formula (II) may be prepared by
06 reacting a compound of formula (IV):
07



16 wherein R_1 , R_2 , R_3 and R_4 are as defined
17 hereinbefore, with a compound of formula (V):
18
19



22 or a salt thereof, wherein R_8 is as defined
23 hereinbefore; and optionally converting the hydroxy
24 group for R_5 in the resulting compound of formula (II).
25 into a C_{1-6} alkoxy or C_{2-7} acyloxy group.
26


27 The reaction is normally carried out in a solvent,
28 such as a C_{1-4} alcohol, in particular methanol, ethanol
29 or propanol at an ambient or an elevated temperature,
30 for example 12 to 100°C. The reaction proceeds
31 particularly smoothly if carried out in ethanol under
32 reflux.
33

34 The resulting compound of formula (II) may be
35 removed from the reaction mixture by removal of the
36 solvent, for example, by evaporation under reduced
37 pressure. Any epoxide impurity may be removed
38 conventionally, for example by chromatography.
39

0095316

The optional conversion of the hydroxy group for R₅' in the resulting compound of formula (II) into a C₁-6 alkoxy or C₂-7 acyloxy group may be carried out as described hereinbefore in relation to the corresponding conversion of R₅ in a compound of formula (I).


A compound of formula (IV) may be prepared, preferably in situ, by reacting a compound of formula (VI):



wherein R₁' , R₂' , R₃ and R₄ are as defined hereinbefore and the hydroxy group is trans to the bromo atom, with a base, such as potassium hydroxide, in a solvent, such as ether or aqueous dioxan.

Compounds of formula (VI) are known and may be prepared in accordance with any appropriate known process, for example, by the process described in the aforementioned U.S. patents and European patent publications. Schematically, such process can be depicted thus.

0095316



- (a) Room temperature; NaOH/40% benzyltrimethylammonium hydroxide in methanol;
- (b) Heat in o-dichlorobenzene;
- (c) N-bromosuccinimide/dimethylsulphoxide/water;
- (d) Bromine in carbon tetrachloride; and
- (e) Acetone/water.

The above process may produce mixtures of compounds during reaction (b) owing to the two sites available for ring formation. It is therefore

0095316


advisable to remove any of the undesired compound by, for example, chromatography, before reaction (c) or (d).

As mentioned previously, the compounds of formula (I) exist in optically active forms, and the processes of the present invention produce mixtures of such forms. The individual isomers may be separated one from the other by chromatography using a chiral phase.

It is preferred that the compounds of formula (I) are isolated in substantially pure form.

The compounds of formula (II) and (V) are also known or can be prepared analogously to the preparation of known compounds.

A number of the compounds of formula (II) are known from the aforementioned US Patents and European Patent publications. However, there is a novel class of compounds falling within formula (II) which are of formula (VII):



wherein either one of R_1 and R_2 is hydrogen and the other is C₁-6 alkylcarbonyl, C₁-6 alkoxy carbonyl, C₁-6 alkylcarbonyloxy, C₁-6 alkylhydroxymethyl or cyano or one of R_1 and R_2 is C₁-6 alkylcarbonyl, nitro or cyano and the other is amino and R_8 is methyl or ethyl; the R_8 -NH group being trans to the hydroxy group;

A preferred sub-class of compounds of formula (VII) are those wherein the alkyl groups or alkyl moieties of alkyl-containing groups are methyl or ethyl.

The compounds of formula (VII) are particularly useful intermediates, which can be prepared as described hereinbefore and which represent part of the present invention.

As mentioned previously, the compounds of formula (I) have been found to have blood-pressure lowering activity. They are therefore useful in the treatment of hypertension.

The present invention accordingly provides a pharmaceutical composition which comprises a compound of this invention and a pharmaceutically acceptable carrier. In particular, the present invention provides an anti-hypertensive pharmaceutical composition which comprises an anti-hypertensive effective amount of a compound of this invention and a pharmaceutically acceptable carrier.

The compositions are preferably adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration for patients suffering from heart failure.

In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit-dose. Suitable unit dose forms include tablets, capsules and powders in sachets or vials. Such unit dose forms may contain from 1 to 100 mg of a compound of the invention and more usually from 2 to 50 mg, for example 5 to 25 mg such as 6, 10, 15 or

0095316

12 20 mg. Such compositions may be administered from 1 to
13 6 times a day, more usually from 2 to 4 times a day, in
14 a manner such that the daily dose is from 5 to 200 mg
15 for a 70 kg human adult and more particularly from 10
16 to 100 mg.

17
18 The compositions of the invention may be
19 formulated with conventional excipients, such as a
20 filler, a disintegrating agent, a binder, a lubricant,
21 a flavouring agent and the like. They are formulated
22 in conventional manner, for example in a manner similar
23 to that used for known anti-hypertensive agents,
24 diuretics and β -blocking agents.

25
26 The present invention further provides a compound
27 of the invention for use in the treatment of
28 hypertension.

29
30 The present invention yet further provides a
31 method of treating hypertension in mammals including
32 man, which comprises administering to the suffering
33 mammal an anti-hypertensive effective amount of a
34 compound or a pharmaceutical composition of the
35 invention.

36
37 The following descriptions relate to the
38 preparation of intermediates and the following examples
39 relate to the preparation of a compound of formula (I).
40

Description 1

6-Cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo-
[b]-pyran

4-Cyanophenol (19.60 g), sodium hydroxide (9.90 g), 40% benzyltrimethylammonium hydroxide in methanol (34.50 g) and 3-methyl-3-chlorobutyne (25.50 g) were stirred in water (150 ml) and dichloromethane (150 ml) for 5.5 days at room temperature. After separation of the layers, the aqueous layer was extracted twice with chloroform, and the combined organic phase evaporated leaving a gum which was taken up in ether and washed three times with 10% sodium hydroxide solution and with water before drying over magnesium sulphate. Removal of drying agent and solvent gave a viscous liquid having absorptions in the IR (film) at 2100, 2220, 3290 cm^{-1} . This liquid (20.91 g) was heated in o-dichlorobenzene (40 ml) at reflux temperature for 1.5 hours under nitrogen. After distillation of the solvent the fraction boiling at 110-114 $^{\circ}$ /0.02 mmHg (16.57 g) was collected, which on standing formed a low melting solid, having an IR absorption at 2230 cm^{-1} . (See M. Harfenist and E. Thom, J. Org. Chem., 37, 841 (1972) who quote m.p. 36 - 37 $^{\circ}$).

Addition to this 6-cyanochromene (16.50 g) dissolved in dimethyl sulphoxide (150 ml) containing water (3.24 ml), of N-bromosuccinimide (31.90 g) with vigorous stirring and cooling, followed by dilution with water and extraction via ethyl acetate gave a mixture which was boiled in acetone (300 ml) and water (100 ml) for 5 hours to hydrolyse the small amount of 3,4-dibromide present. Evaporation of solvents gave 6-Cyano-trans-3-bromo-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-4-ol as white crystals (24.37 g). A small sample had m.p. 128 - 128.5 $^{\circ}$ from 60 - 80 $^{\circ}$

petroleum ether, nmr (CDCl_3).

1.43 (3H), 1.62 (3H), 7.48 (1H, exchangeable) 4.07 (1H, d, $J=9$), 4.87 (1H, d, $J=9$), 6.80 (1H, d, $J=8$), 7.43 (1H, q, $J=8$ 2), 7.78 (1H, d, $J=2$). Anal. Calcd. for $\text{C}_{12}\text{H}_{12}\text{NO}_2\text{Br}$: C, 51.07; H, 4.26; N, 4.96; Br, 28.37. Found: C, 50.95; H, 4.38; N, 5.03; Br, 28.39%.

The bromohydrin (24.30 g) was stirred with sodium hydroxide pellets (5.00 g) in water (250 ml) and dioxan (200 ml) for 3 hours at room temperature. The solvents were removed by distillation under high vacuum and the residue taken up in ether and washed with water and brine before drying over magnesium sulphate. Removal of drying agent and solvent and gave crude 6-cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran (16.02 g) as a gum, having an absorption at 2230cm^{-1} in the IR and Nmr (CCl_4) 1.26 (3H), 1.54 (3H), 3.40 and 3.80 (each 1H, d, $J=4$), 6.77 (1H, d, $J=8$), 7.43 (1H, q, $J=8$, 2), 7.58 (1H, d, $J=2$).

Description 2

7-Acetamido-3,4-dihydro-2,2-dimethyl-6-nitro-3,4-epoxy-2H-benzo-[b]pyran

2,2-Dimethyl-7-nitro-2H-benzo[b]pyran (40.00g, the preparation of which is disclosed in British Patent 1,548,222), glacial acetic acid (200 ml), acetic anhydride (120 ml) and electrolytic iron powder (88 g) were stirred and heated at 120°C for 16 hours. Dilution with water, extraction via chloroform followed by washing of the organic layer with water and sodium bicarbonate solution, drying evaporation etc., gave a crude gum which was chromatographed on a silica gel column using ethyl acetate -60° -80° petroleum ether mixtures in a gradient elution technique. Fractions homogeneous by TLC were combined and recrystallised from 60-80° petroleum ether to give 7-acetamido-2,2-dimethyl-2H-benzo[b]pyran (5.27 g) as white needles of mp 80 - 81°C; nmr (CDCl₃) 1.39 (6H), 2.12 (3H), 5.48 (1H, d, J=10), 6.21 (1H, d, J=10), 6.76-7.34 (3H, m), 8.95 (1H). Anal. Calcd for C₁₃H₁₅NO₂; C, 71.87; H, 6.96; N, 6.45. Found: C, 72.00; H, 7.11; N, 6.23%.

To this acetamidobenzopyran (5.17 g) dissolved in glacial acetic acid (29 ml) was added fuming nitric acid (1.70 ml) dropwise with stirring at 0°C. Dilution with water and extraction via ethyl acetate gave a yellow solid (6.63 g) which was chromatographed on a silica gel column using ethyl acetate - 60-80° petroleum ether mixtures in a gradient elution technique. The least polar component was recrystallised as yellow needles of 7-acetamido-2,2-dimethyl-6-nitro-2H-benzo[b]pyran (1.80 g) of mp 148-150°C from ethanol; nmr (CDCl₃) 1.47 (6H), 2.28 (3H), 5.72 (1H, d, J=10), 6.33 (1H, d, J=10)

02 7.93 (1H), 8.25 (1H). Anal. Calcd for $C_{13}H_{14}N_2O_4$: C,
03 59.54; H, 5.38; N, 10.69. Found: C, 59.61; H, 5.41; N,
04 10.69%.

05
06 To this nitro compound (1.80 g) dissolved in
07 dimethyl sulphoxide (25 ml) and water (0.25 ml) was
08 added N-bromosuccinimide (2.47 g) in one portion and
09 with vigorous stirring. After dilution with water,
10 extraction via ethyl acetate gave a yellow solid (2.59
11 g). A small portion recrystallised from ethanol gave
12 7-acetamido-trans-3-bromo-3,4-dihydro-2,2-dimethyl-6-
13 nitro-2H-benzo[b]pyran-4-ol as yellow needles mp
14 205-206°; n.m.r. ($CDCl_3$) 1.45 (3H), 1.63 (3H), 2.25
15 (3H), 4.07 (1H, d, J=9), 4.78 (1H, d, J=9), 8.08 (1H),
16 8.41 (1H), 10.31 (1H). Anal. Calcd for $C_{13}H_{15}BrN_2O_5$:
17 C, 43.45; H, 4.18; N, 7.80; Br, 22.28. Found C, 43.99;
18 H, 4.39; N, 8.35; Br 22.02%.

19
20 This bromohydrin (2.50 g), sodium hydroxide
21 pellets (4.00 g), water (20 ml) and dioxan (100 ml)
22 were stirred at room temperature for 40 min. Dilution
23 with water (1 litre) and extraction via ethyl acetate
24 gave a crude yellow solid (2.00 g).
25

Description 36-Acetamido-3,4-dihydro-2,2-dimethyl-7-nitro-3,4-epoxy-2H-benzo[b]pyran

To 6-Acetamido-2,2-dimethyl-7-nitro-2H-benzo[b]pyran...
(10.78g, the preparation of which was disclosed in U.K. Patent 1,548,222) dissolved in dimethyl sulfoxide (100 ml) containing water (1.48 ml), was added freshly recrystallised N-bromosuccinimide (14.59g) with vigorous stirring. Dilution with water (700 ml) and filtration and drying of the solid obtained gave 6-Acetamido-trans-3-bromo-3,4-dihydro-2,2-dimethyl-7-nitro-2H-benzo[b]pyran-4-ol as a yellow solid (14.06g). A small portion recrystallised from ethanol had m.p. 198-200°; nmr (CDCl₃/DMSO-d₆) δ 1.62 (3H), 1.79 (3H), 2.37 (3H), 4.27 (1 exchangeable H, m) overlapped with 4.35 (1H, d, J=9), 5.01 (1H, d, J=9), 7.83 (1H), 8.56 (1H), 10.02 (1 exchangeable H, m). Anal. Calcd for C₁₃H₁₅N₂O₅Br: C, 43.47; H, 4.21; N, 7.80. Found: C, 43.70; H, 4.37; N, 7.46%.

This bromohydrin (14.02g), sodium hydroxide pellets (14.00g) dioxan (750 ml) and water (140 ml) were stirred at room temperature during 3 hours. Evaporation to half volume and addition of water (1 L) and extraction via ethyl acetate (3 x 500 ml), and washing of the combined organic layers with water and brine, drying and solvent removal gave a red gummy solid (11.12g). Recrystallisation from ethanol gave 6-acetamido-3,4-dihydro-2,2-dimethyl-3,4-epoxy-7-nitro-2H-benzo[b]pyran as a yellow solid (5.92g) of m.p. 156-158°; nmr δ (CDCl₃) 1.27 (3H), 1.60 (3H), 2.25 (3H), 3.53 (2H, d, J=4), 3.98 (1H, d, J=4), 7.62 (1H), 8.77 (1H), 10.05 (1H). Manipulation of the mother liquors gave an additional crop of epoxide (0.74g). Anal. Calcd for C₁₃H₁₄N₂O₅: C, 56.11; H, 5.07; N, 10.07. Found: C, 55.92; H, 5.27; N, 9.82%.

0095316

Description 4

6-Chloro-3,4-dihydro-2,2-dimethyl-trans-3-bromo-4-hydroxy-2H-benzo[b]pyran

5 The title compound was prepared analogously to the preparation of the 3-bromo-4-hydroxy compound of Description 1 giving a crude crystalline solid.

10 NMR (CDCl₃): δ 1.35 (3H, s)
1.53 (3H, s)
3.22 (2H, m)
4.00 (1H, d, J=9Hz)
4.77 (1H, d, J=9Hz)
6.51 (1H, d, J=8Hz)
7.03 (1H, q, J=8,2Hz)
7.30 (1H, narrow m).


Description 5

6-Chloro-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo-
[b]pyran

5 The crude crystalline solid (10.27g) of Description 4
was dissolved in dimethyl sulphoxide (50 ml) and treated
with sodium hydride (1.06g, 80% dispersion on oil) over
a period of an hour. The resulting material was used
as such in Example 9 after addition of water and extraction
with ethyl acetate.

Description 6

Preparation of 6-acetamido-trans-4-amino-3,4-dihydro-2,2-dimethyl-7-nitro-2H-benzo[b]pyran-3-ol




6-Acetamido-3,4-epoxy-3,4-dihydro-2,2-dimethyl-7-nitro-2H-benzo[b]pyran (1.0 g) was dissolved in dry ethanol (150 ml) and saturated with ammonia during 3h, with cooling. The reaction mixture was stirred at room temperature for 5 days and evaporated. The crude residue was purified on the chromatotron (80% ethyl acetate-pentane to 20% methanol-ethyl acetate gradient elution), to give the title compound (410 mgm). A small portion was converted to the hydrochloride salt and recrystallised from ethanol-diethyl ether, with m.p. 258-261°C.

Anal. Calc. for $C_{13}H_{18}N_3O_5Cl$: C, 47.0; H, 5.47; N, 12.66; Cl, 10.72. Found: C, 46.92; H, 5.58; N, 12.19; Cl, 10.74%

0095316

Description 7


Preparation of 7-acetamido-trans-4-amino-3,4-dihydro-2,2-dimethyl-6-nitro-2H-benzo[b]pyran-3-ol



5 7-Acetamido-3,4-epoxy-3,4-dihydro-2,2-dimethyl-6-nitro-2H-benzo[b]pyran (0.76 g,) was dissolved in dry ethanol and saturated with dry ammonia, and stirred at room temperature for 21hr. Evaporation gave a crude mixture which was purified on the chromatotron (using pentane-ethyl acetate in a gradient elution), to give the title compound (280 mg).

Example 1

Trans-4-N-acetylethylamino-6-cyano-3,4-dihydro-2,2-
dimethyl-2H-benzo[b]pyran-3-ol (Compound 1)



(I)

6-Cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-
2H-benzo- [b]pyran (1.01 g) was stirred in 30%
ethylamine in ethanol solution (10 ml) for four days at
room temperature. Evaporation gave a brown gum (1.20
g) which solidified on standing.

This solid (423 mg), anhydrous sodium acetate
(140 mg) and acetic anhydride (8 ml) was warmed for 3
hrs at 35-40°C with exclusion of moisture. On cooling
the mixture was poured into ice-water and extracted
with ethyl acetate. This was washed with water and
brine before drying over MgSO₄, and evaporation gave an
oil (410 mg) which was chromatographed using a
chromatotron (2 mm silica gel HF₂₅₄ plate; solvent flow
6 ml/min). Elution with 40% ethyl acetate-petroleum
ether gave, in addition, to starting material, the
title compound (230 mg) which was recrystallised from
ethyl acetate (210 mg), m.p. 168 - 170°C.

IR (Nujol) 3300, 2230, 1620 cm⁻¹


Mass Spectrum (E.I.) M⁺ at M/z 288

Anal. C₁₆H₂₀N₂O₃ requires: C, 66.65; H, 6.99; N, 9.72
C, 66.76; H, 7.03; N, 9.73%

0095316

Example 2

Trans-4-N-acetylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol (Compound 2)



(2)

6-Cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran (10.0 g) was stirred in ethanol (20 ml) and the ammonium hydroxide solution (50 ml) for 4 days at room temperature. Evaporation gave a yellow gum (10.1 g) which solidified on standing.

This solid (1.0 g), anhydrous sodium acetate (2.00 g) and acetic anhydride (20 ml) were stirred for 5 hours at room temperature. The mixture was poured into water and extracted with ethyl acetate. This was washed with water and brine, and dried over $MgSO_2$. Removal of drying agent, and evaporation gave a solid which was chromatographed using a chromaton (2 mm silica gel HF25 plate, solvent flow 6 ml/min elution with ethyl acetate-pentane using a gradient technique gave a fraction which contained the crude title compound. Recrystallisation of this material from ethyl acetate gave trans-4-N-acetylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol (208 mgm) as crystals of m.p. 203-250.

01
02
03
04
05
06
07
08
09
10
11
12

-31-

0095316


NMR (CDCl₃-DMSO-d₆) 1.25 (3H, s), 1.47 (3H, s), 2.08
(3H, s), 3.60 (q, J=9, 5Hz), 4.93 (q, J=9, 8Hz), 5.24
(d, J=5 Hz), 6.86 (d, J=8 Hz), 7.43 (q, J=8, 2 Hz)
overlapping 7.50 (d, J=2 Hz) 8.00 (d, J=8 Hz).

Anal. C₁₄H₁₆H₂O₃ requires: C, 64.60; H, 6.20; N, 10.76
found: C, 64.51; H, 6.21; N, 10.78%

0095316

Example 3

Trans-6-cyano-3,4-dihydro-2,2-dimethyl-4-N-propionyl-
amino-2H-benzo[b]pyran-3-ol (Compound 6)



(6)

Trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol (1.19g , prepared by treatment of the corresponding 3,4-epoxide with ethanolic ammonium hydroxide), sodium hydroxide pellets (0.2 g) and water (10 ml) was stirred with chloroform (20 ml) under N₂ for 0.5 hr. Bromopropionyl chloride (0.51 ml) was added in one portion and the mixture stirred vigorously for 0.5 hr. Separation of the layers, was followed by further extraction of the aqueous with chloroform. The combined organic extracts were washed with water and brine before drying over MgSO₄. Filtration and evaporation of solvent gave the bromo amide as a pale yellow solid (1.10g) having a molecular ion at m/z 334.0321 on mass spectrometric examination.

To a stirred suspension of sodium hydride (177 mg, 80% dispersion in oil) in dry tetrahydrofuran (20 ml) under nitrogen was added the crude amide (1.04 g) dissolved in dry tetrahydrofuran (20 ml) during 2 min. A white solid slowly formed as the mixture was stirred


0095316

for 4.5 hours at room temperature. Addition of water and extraction via ethyl acetate with water and brine washing, followed by drying over MgSO_4 , filtration and evaporation gave the title compound as crystals (240 mg) of mp 194-195.5°C from ethyl acetate.

NMR (CDCl_3 and DMSO-d_6) 1.30 (3H, s), 1.50 (3H, s), 3.68 (1H, d, $J=9$ Hz), 4.83 (1H, brm-exchangeable with D_2O), 5.10 (1H, d, $J=9$ 9Hz), 5.71 (1H, q, $J=7, 6\text{Hz}$), 6.34 (1H, d, $J=7$ Hz), overlapping 6.36 (1H, d, $J=6$ Hz), 6.26 (1H, d, $J=9$ Hz), 7.43 (1H, q, 9, 2Hz) overlapping 7.51 (1H, d, $J=2$ Hz), 7.75 (1H, d, $J=9$ Hz).

Example 4

Trans-4-(N-Acetyl)ethylamino-6-cyano-3,4-dihydro-2,2-
dimethyl-2H-benzo[b]pyran-3-yl acetate



5 When the product of stirring 6-cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran with ethanolic ethylamine was heated under reflux in acetic anhydride containing a little pyridine for 16 hours, the title compound was obtained after chromatography and recrystallisation from hexane-ethyl acetate as crystals of mp 125-128°C.


10 IR (KBr disc) 2225, 1745, 1655 cm^{-1}

Anal. Calcd. for $\text{C}_{18}\text{H}_{22}\text{N}_2\text{O}_4$; C, 65.41; H, 6.71; N, 8.48.

Found: C, 64.97; H, 6.62; N, 8.39%

Example 5


Trans-4-(N-Acetyl)methylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol



- 5 6-Cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran (1.00g) was stirred in ethanol (30 ml) containing 40% aqueous methylamine (1.96g) for 3.75 days. Evaporation gave a gum which was dissolved in 2N hydrochloric acid and extracted with ether. The acid solution was basified with 10% sodium hydroxide solution and the liberated amine isolated via ethyl acetate.
- 10 The crude methylaminoalcohol (0.7g) was stirred with anhydrous sodium acetate (1.4g) in acetic anhydride (24 ml) at room temperature for 48 hours. A solid formed and this was collected by filtration. The filtrate was taken up in chloroform and washed several times with
- 15 water and saturated sodium bicarbonate solution. The chloroform layer was dried over magnesium sulphate. After filtration and evaporation the solid residue was recrystallised from ethyl acetate to give the title compound (100mg) as crystals of mp 197-198°C.
- 20 Mass spectrum (EI) shows $M^+ - H_2O$ at 256.1233
- Anal. Calcd for $C_{17}H_{20}N_2O_3$: C, 65.68; H, 6.61, N, 10.21.
- Found: C, 65.60; H, 6.63; N, 10.13%


Example 6

Trans-4-N-Acetylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-yl acetate




When the product of stirring 6-cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran with ethanolic ammonium hydroxide was treated with anhydrous sodium acetate and acetic anhydride during 24 hours, at room temperature, the title compound was obtained as crystals of mp 181-183°C ethyl acetate.

	NMR (CDCl ₃) δ	1.33 (6H, s)
10		2.03 (3H, s)
		2.09 (3H, s)
		4.89 (1H, d, J=9Hz)
		5.22 (1H, t, J=9, 9Hz)
		6.07 (1H, d, J=9Hz)
15		6.85 (1H, d, J=8Hz)
		7.32 (1H, q, J=8,2Hz) overlapping
		7.37 (1H, d, J=2Hz)

Example 7Trans-4-N-Propionylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol

The product (0.46g, obtained by stirring 6-cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran with
 5 ethanolic ammonium hydroxide), and triethylamine (0.3 ml) were stirred in dichloromethane at 0°C for 0.5 hr. Propionyl chloride (0.20g) was added and the reaction mixture stirred for a further 0.5 hr. with cooling to 0°C. The reaction mixture was allowed to attain room
 10 temperature, and was washed with water and brine before drying over anhydrous magnesium sulphate. Removal of drying agent and evaporation left a solid which was recrystallised from ethyl acetate to give the title amide (147 mg) as crystals of mp 115-117°C.

15	NMR (CDCl ₃) δ	1.24 (3H, t, J=8, 8Hz)
		1.23 (3H, s)
		1.50 (3H, s)
		2.38 (2H, q, J=8, 8, 8Hz)
		3.65 (1H, d, J=9Hz)
20		4.27 (1H exchangeable)
		5.05 (1H, t, J=9, 8Hz, collapsing to d, J=9Hz on addition of D ₂ O)
		6.13 (1H, d, J=8Hz, exchangeable)
		6.88 (1H, d, J=8Hz)
25		7.45 (1H, q, J=8, 2Hz)
		7.55 (1H, d, J=2Hz)

Example 8Trans-4-N-Valeryl-amino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol


The product (0.51g, obtained from the action of ethanolic ammonium hydroxide on 6-cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran), and triethylamine (0.32 ml) were stirred in dichloromethane for 0.5 hr. at 0°C. Valeryl chloride (0.28 ml) was added and the reaction mixture stirred for a further 0.5 hr. at 0°C. The mixture was allowed to reach room temperature, and was washed with water and brine before drying over anhydrous magnesium sulphate. Removal of drying agent and solvent left a solid which was recrystallised from ethyl acetate-pentane to yield the title amide (0.24g) as crystals of m.p. 158-159°C

NMR (CDCl₃) δ 0.95 (3H, irreg t)
 1.26 (3H, s) and 1.50 (3H, s) overlapping 1.15-1.90 (4H, m)
 2.34 (2H, irreg t, J=7Hz)
 3.61 (1H, d, J=9Hz)
 4.25 (1H, m)
 5.05 (1H, t, J=9, 8Hz)
 6.08 (1H, d, J=8Hz)
 6.87 (1H, d, J=8Hz)
 7.44 (1H, q, J=8, 2Hz) overlapped by
 7.53 (1H, d, J=2Hz)

Anal. Calcd for C₁₇H₂₂N₂O₃: C, 67.53; H, 7.33; N, 9.26. Found
 C, 67.84; H, 7.46; N, 9.51%

Example 9

Trans-4-N-Acetylamino-6-chloro-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol



6-Chloro-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran (3.0g), ammonium hydroxide solution (15.5 ml) and ethanol (6.0 ml) were stirred at room temperature for 3.75 days. Evaporation gave a solid which was taken up in ethyl acetate. The organic phase was extracted with 5N Hydrochloric acid, and the aqueous phase basified with 10% sodium hydroxide solution. Extraction with ethyl acetate, drying over anhydrous magnesium sulphate, filtration and evaporation gave the 4-amino-3-ol (1.74g).

The crude aminoalcohol (0.5g) and triethylamine (0.36 ml) were stirred in dichloromethane (15 ml) for 0.5 hr. Acetyl chloride (0.18 ml) was added in one portion with cooling to 0°C and the reaction stirred vigorously for a further 0.5 hr. The reaction mixture was allowed to attain room temperature and was washed with water and brine, dried over anhydrous magnesium sulphate, filtered and evaporated. The crude solid so obtained was recrystallised from ethyl acetate to give the title amide (130 mg) as crystals of mp 186-188°C


0095316

NMR (CDCl₃) δ 1.23 (3H, s)
1.47 (3H, s)
2.15 (3H, s)
3.60 (1H, q, J=9, 3Hz)
4.20 (1H, d, J=3Hz)
4.97 (1H, t, J=8, 8Hz)
5.85 (1H, m)
6.77 (1H, d, J=9Hz)
7.05 - 7.30 (2H, m)

0095316

Example 10

Trans-6-Acetyl-4-N-acetylamino-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol



5 6-Acetyl-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran (2.0g, prepared as described in example 1 of U.K. patent No. 1, 511, 187) was dissolved in ethanol (100 ml) and saturated with ammonia. The solution was stirred for 72 hours at room temperature. Evaporation gave a white solid which was subjected to the same acid-base treatment used to purify the 4-amino-3-ol of example 9.

10 The aminoalcohol so obtained (0.75g) was stirred with triethylamine (0.44 ml) in dichloromethane (20 ml) for 0.5 hr. Acetylchloride (0.24 ml) was added in one portion with cooling to 0°C to this solution, and stirring was continued for 0.5 hr. The solution was allowed to
15 attain room temperature, and then washed with water and brine before drying over anhydrous magnesium sulphate. Filtration and evaporation gave a solid which was recrystallised from ethyl acetate-pentane to give the title compound (200 mg) as crystals of mp 182-183°C.

20 NMR (CDCl₃) δ 1.25 (3H, s)
1.47 (3H, s)
1.18 (3H, s)
2.30 (3H, s)
3.60 (1H, q, J=9, 5Hz)

0095316

5


4.96 (1H, t, J=9, 9Hz)
5.21 (1H, d, J=5Hz)
6.78 (1H, d, J=8Hz)
7.76 (1H, q, J=8, 3Hz) overlapped by
7.83 (1H, d, J=3Hz)
8.04 (1H, d, J=9Hz)

Mass Spectrum (EI) shows M^+ at M/Z 277.1311
Calcd for $C_{15}H_{19}NO_4$: 277.1314

0095316

Example 11

Trans-4,6-bis(Acetylamino)-3,4-dihydro-2,2-dimethyl-7-nitro-2H-benzo[b]pyran-3-ol




The compound of description 6 (210 mg), sodium hydroxide pellets (30 mg), water (2.5 ml) and chloroform (7 ml) were stirred together before addition of acetyl chloride (58 mg). The reaction mixture was stirred for 0.5 hr. before addition of water (10 ml) and chloroform (10 ml) and separation of the layers. The aqueous layer was further extracted with chloroform and the organic layers combined and dried over anhydrous magnesium sulphate. Removal of drying agent and solvent gave a yellow-orange solid which was recrystallised from ethyl acetate to give the title compound (45 mg) mp 244-246°C.

NMR (CDCl₃-DMSO d₆) δ 1.23 (3H, s)
 1.45 (3H, s)
 2.03 (3H, s)
 2.09 (3H, s)
 3.60 (1H, q, J=9, 5Hz)
 4.87 (1H, t, J=9, 9Hz)
 5.37 (1H, d, J=5Hz)
 7.30 (1H, s)
 7.58 (1H, s)
 8.17 (1H, d, J=9Hz)
 9.84 (1H, s)

Mass spectrum (EI) shows M⁺ at M/Z 337.1279
 Calcd. for C₁₅H₁₉N₃O₆: 337.1274

Example 12

Trans-4,7-bis (Acetylamino)-3,4-dihydro-2,2-dimethyl-6-nitro-2H-benzo[b]pyran-3-ol




The compound of description 7 (90 mg) and triethylamine (0.04 ml) were stirred in dichloromethane (10 ml) for 0.5 hr. at room temperature. Acetyl chloride (0.02 ml) was added to the reaction mixture with cooling to 0°C, and stirring continued for 0.5 hr. after addition. After the reaction mixture had reached room temperature, the organic phase was washed with water, dried over anhydrous magnesium sulphate and evaporated. The residue was recrystallised from ethyl acetate to give the title compound (24 mg) as crystals of mp 256-259°C.

Mas spectrum (EI): $M^+ - H_2O$ at M/Z 319.1171

Calcd for $C_{15}H_{17}N_3O_5$: 319.1168

0095316


Example 13Trans-4-Chloroacetyl-amino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]-pyran-3-ol

The amino alcohol (4.0 g, obtained by stirring 6-cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran with ethanolic ammonium hydroxide), and triethylamine (2.55 ml) were stirred in dichloromethane (120 ml) for 0.5 hr. Chloroacetyl chloride (1.46 ml) was added in one portion with cooling to 0°C, and the reaction mixture stirred for a further 0.5 hr. before being allowed to attain room temperature. The reaction mixture was washed with water, brine, and dried over anhydrous magnesium sulphate. The solution was filtered and evaporated to give a grey coloured solid. Two recrystallisations from ethyl acetate gave the title compound (1.48 g) of m.p. 196-197°C.

NMR (CDCl₃ + DMSO-d₆) δ 1.38 (3H, s)
 1.51 (3H, s)
 3.60 (1H, d, J=9Hz)
 4.14 (2H, s)
 4.90 (1H, t, J=9,9Hz)
 6.81 (1H, d, J=9,HZ)
 7.30-7.57 (2H,m)
 8.46 (1H, d, J=9Hz).

Example 14

4-Acetylamino-6-cyano-2,2-dimethyl-2H-benzo[b]pyran




The compound of example 2, (0.5 g) and sodium hydride (0.058g, 80% dispersion in oil) were heated under reflux in dry xylene (50 ml) in an atmosphere of nitrogen for 48
 5 hours. After cooling, water (25 ml) was added cautiously, and the layers separated. The organic phase was washed with water and brine, and dried over anhydrous magnesium sulphate. Filtration and evaporation gave a gum which was chromatographed (chromatotron, gradient elution: ethyl
 10 acetate-pentane, 2 mm silica gel, 6 ml/min) to give the title compound (230 mg) in the initial fractions, as needles (65 mg) from diethyl ether, having a m.p. of 146-147°C.

15 NMR (CDCl₃) δ 1.50 (6H, s)
 2.23 (3H, s)
 6.37 (1H, s)
 6.90 (1H, d, J=9Hz) overlapping 7.00 (1H, m)
 7.45 (1H, q, J=9, 2Hz) overlapping
 7.52 (1H, d, J=2Hz)

Example 15

0095316

Trans-6-cyano-3,4-dihydro-4-methoxyacetylamino-2,2-dimethyl-2H-benzo[b]pyran-3-ol


5 The aminoalcohol (4.37g, obtained by stirring 6-cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran with ethanolic ammonium hydroxide), and triethylamine (2.79 ml) were stirred in dichloromethane (30 ml) for 0.5 hr. The stirred solution was cooled to 0°C and methoxyacetyl chloride (2.18g) was added in one portion and the reaction mixture stirred for a further 0.75hr, and then allowed to reach room temperature. The reaction mixture was washed with water, brine, and dried over anhydrous magnesium sulphate. The solution was filtered and evaporated to give a solid which was recrystallised from ethyl acetate to give the title compound (3.01g) of mp 162-163°C.

15 NMR (CDCl₃) δ 1.30 (3H, s)
 1.52 (3H, s)
 3.48 (3H, s)
 3.67 (1H, d, J=9Hz)
 4.07 (2H, s)
 20 5.10 (1H, t, J=9,9Hz) collapsing to doublet, J=9Hz on addition of D₂O,
 6.93 (1H, d, J=9Hz) overlapping
 6.95-7.00 (1H, m, exchangeable)
 25 7.50 (1H, q, J=9,2Hz) overlapped by
 7.55 (1H, d, J=2Hz).

0095316

Example 16

Trans-6-cyano-3,4-dihydro-2,2-dimethyl-4-thioacetyl-amino-
2H-benzo[b]pyran-3-ol




The compound of example 2 (520 mg) and Lawesson's
5 reagent (444 mg) were heated under reflux in dry toluene
for 1hr. Evaporation gave a foam which was chromatographed
on 45g of silica gel using chloroform containing up to 10%
ethanol in a gradient elution. Fractions containing the
desired material (0.64g) were combined and recromatographed
10 using a chromatotron (2mm silica gel, flow rate 9ml/min of
chloroform) to give a crude product (110 mg) which on
trituration with hexane gave the title compound as a yellow
solid (68 mg) of mp 176-180°C.

0095316

Example 17

Trans-6-cyano-4-formylamino-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol



The aminoalcohol (0.9g), obtained by stirring 6-cyano-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran with ethanolic ammonium hydroxide, was heated under reflux in formic acid (15ml) and pyridine (1 ml) during 19 hr. The cooled solution was poured into water and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulphate. Filtration and evaporation left an orange coloured oil which was chromatographed (chromatotron, ethyl acetate-pentane gradient elution on silica gel 2 mm, flow rate 9 ml/min.) to give after one recrystallisation from ethyl acetate, the title compound (220 mg), of m.p. 228.5-230.5°C

Mass spectrum M+ AT M/Z 246.0992.

Calcd for C₁₃H₁₄N₂O₃ 246.1004.

Pharmacological Data

Systolic blood pressures were recorded by a modification of the tail cuff method described by I M Claxton, M G Palfreyman, R H Poyser, R L Whiting, European Journal of Pharmacology, 37, 179 (1976). W + W BP recorder, model 8005, was used to display pulses. Prior to all measurements rats were placed in a heated environment ($33.5 \pm 0.5^\circ\text{C}$) before transfer to a restraining cage. Each determination of blood pressure was the mean of at least 6 readings. Spontaneously hypertensive rats (ages 12 - 18 weeks) with systolic blood pressures 170 mmHg were considered hypertensive.

Compound 1 of Example 1	Time Post Dose (Hours)	% Change in Systolic Blood Pressure	% Change in Heart Rate
6 rats	1	-22 ± 5	-6 ± 7
Dose 1 mg/kg po	2	-19 ± 3	-2 ± 3
Initial Blood Pressure	4	-13 ± 2	-6 ± 3
234 ± 7 mmHg	6	-27 ± 4	-7 ± 4
Initial Heart Rate	24	-7 ± 4	-6 ± 1
467 ± 19 beats/min			

Compound 2 of Example 2	Time Post Dose (Hours)	% Change in Systolic Blood Pressure	% Change in Heart Rate
6 rats Dose 0.3mg/kg po	1	- 47 ± 5*	0 ± 4
	2	- 38 ± 4*	1 ± 4
Initial Blood Pressure	4	- 35 ± 2**	-4 ± 5
199 ± 6 mmHg	6	- 30 ± 1	-10 ± 4
Initial Heart Rate	24	- 10 ± 5	-1 ± 1
502 ± 8 beats/min			

* 1 rat had no measurable pulse.


** 2 rats had no measurable pulse.

Toxicity

No toxic effects were observed in the above test.

What we claim is:

1. A compound of formula (I):



wherein:

either one of R_1 and R_2 is hydrogen and the other is selected from the class of C_{1-6} alkylcarbonyl, C_{1-6} alkoxy carbonyl, C_{1-6} alkylcarbonyloxy, C_{1-6} alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C_{1-6} alkylsulphinyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxy sulphinyl, C_{1-6} alkoxy sulphonyl, C_{1-6} alkylcarbonylamino, C_{1-6} alkoxy carbonylamino, C_{1-6} alkyl-thiocarbonyl, C_{1-6} alkoxy-thiocarbonyl, C_{1-6} alkyl-thiocarbonyloxy, C_{1-6} alkyl-thiolmethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C_{1-6} alkyl groups, or C_{1-6} alkylsulphinylamino, C_{1-6} alkylsulphonylamino, C_{1-6} alkoxy sulphinylamino or C_{1-6} alkoxy sulphonylamino or ethylenyl terminally substituted by C_{1-6} alkylcarbonyl, nitro or cyano, or $-C(C_{1-6} \text{ alkyl})NOH$ or $-C(C_{1-6} \text{ alkyl})NNH_2$, or one of R_1 and R_2 is nitro, cyano or C_{1-3} alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C_{1-6} alkyl or by C_{2-7} alkanoyl;

02 one of R₃ and R₄ is hydrogen or C₁₋₄ alkyl and the
03 other is C₁₋₄ alkyl or R₃ and R₄ together with the
04 carbon atom to which they are attached are
05 C₂₋₅ polymethylene;

06
07 either R₅ is hydroxy, C₁₋₆ alkoxy or C₂₋₇ acyloxy
08 and R₆ is hydrogen or R₅ and R₆ together are a bond;

09 hydrogen, or
10 R₇ is C₁₋₆ alkyl optionally substituted by
11 hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl or carboxy,
12 or C₁₋₂ alkyl substituted by halogen, or C₂₋₆ alkenyl;

13
14 R₈ is hydrogen or C₁₋₆ alkyl; and

15
16 X is oxygen or sulphur; the R₈-N-CX-R₇ group being
17 trans to the R₅ group when R₅ and R₆ together are not a
18 bond; or, when one or the other of R₁ and R₂ is an
19 amino or an amino-containing group, a pharmaceutically
20 acceptable salt thereof.

21
22 2. A compound according to claim 1, wherein one of R₁
23 and R₂ is hydrogen, the other is selected from the
24 class of C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxycarbonyl,
25 C₁₋₆ alkylcarbonyloxy, C₁₋₆ alkylhydroxymethyl, nitro
26 or cyano.

27
28 3. A compound according to claim 2, wherein R₂ is
29 hydrogen.

30
31 4. A compound according to claim 1, wherein one of R₁
32 and R₂ is nitro, cyano or C₁₋₃ alkylcarbonyl and the
33 other is amino optionally substituted by one or two
34 C₁₋₆ alkyl or by C₂₋₇ alkanoyl.

35
36 5. A compound according to claim 4, wherein one of R₁
37 and R₂ is nitro or cyano and the other is amino.
38

02 6. A compound according to claim 4, wherein R₁ is
03 nitro, cyano or C₁₋₃ alkylcarbonyl.
04

05 7. A compound according to any one of the preceding
06 claims, wherein the alkyl groups or alkyl moieties of
07 alkyl-containing groups for R₁ or R₂ are methyl or
08 ethyl.
09

10 8. A compound according to any one of the preceding
11 claims, wherein R₃ and R₄ are both C₁₋₄ alkyl.
12

13 9. A compound according to claim 8, wherein R₃ and R₄
14 are both methyl.
15

16 10. A compound according to any one of the preceding
17 claims, wherein R₅ is hydroxy or C₂₋₇ acyloxy and R₆ is
18 hydrogen.
19

20 11. A compound according to any one of claims 1 to 9,
21 wherein R₅ and R₆ together are a bond.
22

23 12. A compound according to any one of the preceding
24 claims, wherein R₇ is ^{hydrogen} C₁₋₆ alkyl optionally substituted
25 by hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl or carboxy
26 or is C₁₋₂ alkyl substituted by halogen.
27

28 13. A compound according to claim 12, wherein R₇ is hydrogen,
29 methyl or ethyl.
30

31 14. A compound according to claim 12, wherein R₇ is
32 methyl or ethyl terminally substituted by hydroxy,
33 methoxy, ethoxy, methoxycarbonyl, ethoxycarbonyl or
34 carboxy.
35

36 15. A compound according to claim 12, wherein R₇ is
37 methyl or ethyl terminally substituted by chloro or
38 bromo.
39

16. A compound according to any one of the preceding claims, wherein R₈ is hydrogen or methyl.

17. A compound according to claim 16, wherein R₈ is hydrogen.


18. Trans-4-N-acetylethylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol;
trans-6-cyano-3-,4-dihydro-2,2-dimethyl-4-N-propionoylamino-2H-benzo[b]pyran-3-ol;
trans-4-(N-acetyl)ethylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-yl acetate;
trans-4-(N-acetyl)methylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol;
trans-4-N-propionylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol;
trans-4-N-valerylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol;
trans-4-N-acetylamino-6-chloro-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol;
trans-4,6-bis(acetylamino)-3,4-dihydro-2,2-dimethyl-7-nitro-2H-benzo[b]pyran-3-ol;
trans-4,7-bis(acetylamino)-3,4-dihydro-2,2-dimethyl-6-nitro-2H-benzo[b]pyran-3-ol;
trans-4-chloroacetylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol;
4-acetylamino-6-cyano-2,2-dimethyl-2H-benzo[b]pyran;
trans-4-methoxyacetylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol;
trans-4-thioacetylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol; or
trans-4-formylamino-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol.

19. Trans-4-N-acetylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol;
trans-4-N-acetylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-yl acetate;
trans-4-N-acetylamino-6-acetyl-3,4-dihydro-2,2-

dimethyl-2H-benzo[b]pyran-3-ol; or
trans-4,7-bis(acetylamino)-6-nitro-3,4-dihydro-2,2
 -dimethyl-2H-benzo[b]pyran-3-ol.

20. A compound according to any one of the preceding
 claims, in substantially pure form.

21. A process for preparing a compound of formula (I),
 as defined in claim 1, which comprises acylating a
 compound of formula (II):



wherein R_1' and R_2' are R_1 and R_2 , as defined
 in claim 1, or a group or atom convertible thereto, R_3 ,
 R_4 and R_8 are as defined in claim 1, R_5' is hydroxy,
 C_{1-6} alkoxy or C_{2-7} acyloxy and R_6' is hydrogen, the
 R_8NH group being trans to the R_5' group, with an
 acylating agent of formula (III):



wherein R_7 is as defined in claim 1, and L_1 is a
 leaving group; in the case where R_1' or R_2' is a group
 or atom convertible into R_1 or R_2 , converting the group
 or atom into R_1 or R_2 ; optionally converting R_1 , R_2 or
 R_5 in the resulting compound of formula (I) into
 another R_1 , R_2 or R_5 ; in the case where R_5 and R_6 in
 the resulting compound of formula (I) are hydroxy and
 hydrogen respectively, optionally dehydrating the
 compound to give another compound of formula (I),
 wherein R_5 and R_6 together are a bond; optionally
 thiating the $R_8-N-CO-R_7$ group in the resulting compound


of formula (I) to give another compound of formula (I), wherein X is sulphur; and, when one or the other of R₁ and R₂ in the resulting compound of formula (I) is amino or an amino-containing group, optionally forming a pharmaceutically acceptable salt.

22. A process according to claim 21, wherein L₁ in the acylating agent of formula (II) is C₂₋₇ acyloxy or C₁₋₄ alkylcarbonyloxy.

23. A pharmaceutical composition, which comprises a compound of formula (I), as defined in any of the claims 1 to 20, and a pharmaceutically acceptable carrier.

24. A compound of formula (I), as defined in any one of claims 1 to 20, for use in the treatment of hypertension.

25. A compound of formula (VII):



wherein either one of R₁ and R₂ is hydrogen and the other is C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxy carbonyl, C₁₋₆ alkylcarbonyloxy, C₁₋₆ alkylhydroxymethyl or cyano or one of R₁ and R₂ is C₁₋₆ alkylcarbonyl, nitro or cyano and the other is amino and R₈ is methyl or ethyl; the R₈NH group being trans to the hydroxy group.



European Patent
Office

EUROPEAN SEARCH REPORT

0095316

Application number

EP 83 30 2824

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 7)
D,A	US-A-4 110 347 (E. WATTS) * Whole document *	1,23-25	C 07 D 311/68 C 07 D 311/70
A	FR-A-2 346 346 (BEECHAM) * Pages 1,5; page 6, lines 22-23; claims *	1,23-25	
D,A	EP-A-0 028 064 (BEECHAM) * pages 1-5, claims *	1,23-25	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 7)
			C 07 D 311/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 17-08-1983	Examiner FRANCOIS J.C.L.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	